| Literature DB >> 22958519 |
Hasse Melbye1, Lisa Joensen, Mette Bech Risør, Peder A Halvorsen.
Abstract
BACKGROUND: Respiratory tract infections (RTIs) may be more severe in those with asthma or COPD and these patients are more frequently in need of health care. The aim of the study was to describe the frequency of RTI symptoms in a general adult population and how care-seeking is associated with the presence of obstructive lung disease.Entities:
Mesh:
Year: 2012 PMID: 22958519 PMCID: PMC3568001 DOI: 10.1186/1471-2466-12-51
Source DB: PubMed Journal: BMC Pulm Med ISSN: 1471-2466 Impact factor: 3.317
Subjects invited to participate in the Tromsø 6 study
| Age 30 – 39 | 10% random sample |
| Age 40 – 42 | All residents |
| Age 43 – 59 | 40% random sample |
| Age 60 – 87 | All residents |
| Attenders to the second visit of Tromsø 4# | All residents if not included above |
| Age 50 – 62 | All attenders to first visit |
| Age 63 – 74 | 20% random sample of attenders to first visit |
| Age 75 – 84 | All attenders to first visit |
| Attenders to the second visit of Tromsø 4# | All attenders to first visit (in Tromsø 6) |
# The whole Tromsø population aged 25 years or more were invited to Tromsø 4 in 1994, and all the attending men aged 55–74 years and the attending women aged 50–74 years were invited to the second visit [12].
Frequency of reporting symptoms of respiratory tract infection last week by characteristics of 6414 middle-aged and elderly adults taking part in the Tromsø 6 survey
| | ||||||||
|---|---|---|---|---|---|---|---|---|
| 798 | 12 | | 8 | | 340 | 5.3 | | |
| Male (n = 2754) | 350 | 13 | 0.6 | 8 | 0.6 | 149 | 5.4 | 0.7 |
| Female (n = 3660) | 448 | 12 | | 8 | | 191 | 5.2 | |
| <55 years (n = 1059) | 141 | 13 | 0.001# | 7 | 0.03£ | 79 | 7.5 | <0.001# |
| 55-64 years (n = 2656) | 354 | 13 | | 9 | | 138 | 5.2 | |
| 65-74 years (n = 1752) | 230 | 13 | | 9 | | 217 | 5.5 | |
| ≥ 75 Years (n = 947) | 947 | 8 | | 14 | | 123 | 2.7 | |
| Current (n = 1158) | 214 | 19 | <0.001# | 11 | 0.01£ | 76 | 6.6 | 0.7 |
| Previous (n = 2955) | 334 | 11 | | 8 | | 132 | 4.5 | |
| Never (n = 2210) | 240 | 11 | | 7 | | 126 | 5.7 | |
| Winter (November-April) (n = 3128) | 425 | 14 | 0.007 | 9 | 0.2 | 175 | 5.6 | 0.3 |
| Summer (May-October) (n = 3286) | 373 | 11 | | 8 | | 165 | 5.0 | |
| Asthma, not COPD (n = 457) | 69 | 15 | 0.07 | 11 | 0.5 | 28 | 6.1 | 0.4 |
| COPD, not asthma (n = 172) | 25 | 15 | 0.4 | 14 | 0.09 | 6 | 3.5 | 0.3 |
| Both asthma and COPD (n = 141) | 22 | 16 | 0.3 | 12 | 0.5 | 9 | 6.4 | 0.6 |
| Neither asthma nor COPD (n = 5578) | 679 | 12 | 0.09 | 8 | 0.1 | 296 | 5.3 | 1.0 |
| Cardiovascular disease (n = 1154) | 134 | 12 | 0.3 | 12 | 0.02 | 47 | 4.1 | 0.04 |
| Good/exellent (n = 3949) | 449 | 11 | 0.001# | 8 | 0.01£ | 207 | 5.2 | 0.9 |
| Neither good nor bad (n = 2057) | 288 | 14 | | 10 | | 109 | 5.3 | |
| Bad/very bad (n = 347) | 53 | 15 | | 14 | | 19 | 5.5 | |
| Normal/restrictive (n = 4881) | 567 | 12 | <0.001# | 8 | <0.001£ | 267 | 5.5 | 0.2# |
| GOLD 1 (n = 643) | 80 | 12 | | 11 | | 26 | 4.0 | |
| GOLD 2–4 (n = 781) | 134 | 17 | | 13 | | 31 | 4.6 | |
| Asthma or COPD not reported, FEV1/FVC ≥ 0.7 (n = 4436) | 511 | 12 | 0.001 | 8 | 0.009 | 235 | 5.3 | 0.7 |
| Asthma or COPD reported, FEV1/FVC ≥ 0.7 (n = 445) | 56 | 13 | 0.9 | 7 | 0.09 | 32 | 7.2 | 0.05 |
| Asthma or COPD reported, FEV1/FVC <0.7 (n = 380) | 61 | 16 | 0.03 | 14 | <0.001 | 11 | 2.9 | 0.04 |
| Asthma or COPD not reported but GOLD 1 spirometry (n = 559) | 69 | 12 | 1.0 | 9 | 0.9 | 25 | 4.5 | 0.4 |
| but GOLD 2–4 spirometry (n = 485) | 84 | 17 | 0.001 | 12 | 0.04 | 26 | 5.4 | 0.9 |
#Chi-square linear trend.
Subject with and without the condition are compared.
£ Jonckheere-Terpstra test.
Predictors of self-reported symptoms of airway infection the previous seven days (n = 763), and that had started within the previous seven days (n = 319), evaluated by multivariable logistic regression in 5943 middle-aged and elderly adults taking part in the Tromsø 6 survey
| | ||||||
|---|---|---|---|---|---|---|
| 1.06 | 0.90 - 1.24 | 0.5 | 1.13 | 0.90 - 1.43 | 0.3 | |
| 0.95 | 0.76 - 1.17 | 0.6 | 0.67 | 0.50 - 0.90 | 0.008 | |
| 65-74 | 0.94 | 0.74 - 1.19 | 0.6 | 0.77 | 0.56 - 1.06 | 0.1 |
| 75 + | 0.49 | 0.35 - 0.68 | <0.001 | 0.35 | 0.21 - 0.57 | <0.001 |
| 1.60 | 1.29 - 1.98 | <0.001 | 1.12 | 0.82 - 1.54 | 0.5 | |
| previous | 0.99 | 0.82 - 1.19 | 0.9 | 0.80 | 0.61 - 1.03 | 0.09 |
| 1.30 | 1.11 - 1.53 | 0.001 | 1.12 | 0.88 - 1.42 | 0.4 | |
| 1.22 | 0.93 - 1.62 | 0.2 | 1.22 | 0.81 - 1.85 | 0.3 | |
| COPD, not asthma£ | 0.97 | 0.60 - 1.55 | 0.9 | 0.72 | 0.29 - 1.81 | 0.5 |
| Both asthma and COPD£ | 1.06 | 0.65 - 1.64 | 0.8 | 1.33 | 0.63 - 2.81 | 0.5 |
| Cardiovascular disease | 0.91 | 0.73 - 1.13 | 0.4 | 0.79 | 0.56 - 1.12 | 0.2 |
| 1.08 | 0.83 - 1.40 | 0.6 | 0.72 | 0.46 - 1.13 | 0.2 | |
| GOLD 2–4 spirometry | 1.48 | 1.17 - 1.87 | 0.001 | 0.89 | 0.60 - 1.33 | 0.6 |
| 1.27 | 1.09 - 1.50 | 0.002 | 1.15 | 0.92 - 1.45 | 0.2 | |
The area under curve for the two models were 0.60 (0.58-0.62) and 0.60 (0.57-0.63), respectively.
# Age 38–54 years is reference category.
Never smoking is reference category.
£ Asthma or COPD not reported is reference category.
FEV1/FVC ≥ 0.7 is reference category.
Predictors of duration of illness as evaluated by linear regression in 757 subjects reporting symptoms of respiratory tract infection the previous week in the Tromsø 6 survey (r = 0.03)
| 0.05 | 0.2 | |
| 0.03 | 0.4 | |
| 0.05 | 0.3 | |
| previous | −0.01 | 0.8 |
| 0.05 | 0.2 | |
| 0.06 | 0.1 | |
| COPD, not asthma | 0.2 | 0.6 |
| Asthma or COPD | −0.01 | 0.8 |
| Cardiovascular disease | 0.08 | 0.04 |
| −0.01 | 0.8 | |
| GOLD 2–4 spirometry | 0.01 | 0.7 |
Frequency of consulting a doctor and taking antibiotics in 798 subjects reporting symptoms of respiratory tract infection the previous week in the Tromsø 6 survey
| | | ||||
|---|---|---|---|---|---|
| 798 | 41 | 5.1 | 58 | 7.4 | |
| Male | 350 | 19 | 5.4 | 22 | 6.3 |
| Female | 448 | 22 | 4.9 | 36 | 8.0 |
| <45 years | 141 | 4 | 2.8 | 8 | 5.9 |
| 55-64 years | 354 | 20 | 5.6 | 24 | 6.8 |
| 65-74 years | 230 | 14 | 6.1 | 20 | 8.7 |
| ≥ 75 Years | 73 | 3 | 4.1 | 6 | 8.2 |
| Current | 214 | 12 | 5.6 | 12 | 5.6 |
| Previous | 334 | 19 | 5.7 | 27 | 8.1 |
| Never | 240 | 10 | 4.2 | 18 | 7.5 |
| Winter | 423 | 17 | 4.0 | 23 | 5.4£ |
| Summer | 363 | 24 | 6.4 | 35 | 9.4 |
| Good/exellent | 449 | 17 | 3.8& | 29 | 6.6 |
| Neither good nor bad | 288 | 19 | 6.6 | 22 | 7.7 |
| Bad/very bad | 53 | 5 | 9.4 | 7 | 13.5 |
| Asthma or COPD Yes | 119 | 9 | 7.6 | 16 | 13.7 # |
| No | 679 | 32 | 4.7 | 42 | 6.3 |
| Cardiovascular disease Yes | 134 | 11 | 8.2 | 14 | 10.5 |
| No | 664 | 30 | 4.5 | 44 | 6.7 |
| Hypertension Yes | 269 | 14 | 5.2 | 17 | 6.4 |
| No | 529 | 27 | 5.1 | 41 | 7.9 |
| ≤ 2 weeks | 593 | 13 | 2.2 | 25 | 4.3 |
| >2 weeks | 205 | 28 | 13.7μ | 33 | 16.6μ |
| GOLD 1 spirometry | 79 | 5 | 6.3 | 6 | 7.6 |
| GOLD 2–4 spirometry | 134 | 5 | 3.7 | 12 | 9.1 |
| FEV1/FVC ≥ 0.7 | 567 | 31 | 5.5 | 40 | 7.1 |
| No asthma or COPD reported, FEV1/FVC ≥ 0.7 | 511 | 27 | 5.3 | 32 | 6.3 |
| Asthma or COPD reported, FEV1/FVC ≥ 0.7 | 56 | 4 | 7.1 | 8 | 14.3 |
| Asthma or COPD reported, FEV1/FVC < 0.7 | 61 | 5 | 8.2 | 8 | 13.1 |
| No asthma or COPD reported, but GOLD 1 spirometry | 68 | 3 | 4.4 | 4 | 5.9 |
| No Asthma or COPD reported, but GOLD 2–4 spirometry | 84 | 2 | 2.4 | 6 | 7.1 |
£The difference between the two groups is statistically significant, p = 0.03.
& The variation between the three groups is statistically significant (chi-square linear trend), p = 0.03.
# The difference between the two groups is statistically significant, p = 0.005.
μ The difference between the two groups is statistically significant, p < 0.001.
Characteristics of subgroups of the study population (n = 6305) in %, based on spirometry and self-reported asthma or COPD
| | ||||||
|---|---|---|---|---|---|---|
| No asthma or COPD reported, FEV1/FVC ≥ 0.7 (n = 4436) | 42.1 | 36.8 | 46.1 | 14.4 | 15.6 | 3.9 |
| Asthma or COPD reported, but FEV1/FVC ≥ 0.7 (n = 445) | 30.8 | 35.5 | 46.9 | 17.5 | 18.9 | 14.4 |
| Asthma or COPD reported, and FEV1/FVC <0.7 (n = 380) | 44.4# | 61.9 | 57.2& | 26.9£ | 28.1 | 13.9& |
| Asthma or COPD not reported but GOLD 1 (n = 559) | 47.8 | 60.5 | 47.1 | 27.3 | 20.1 | 4.9 |
| but GOLD 2–4 (n = 485) | 55.3 | 57.5 | 45.6 | 38.1 | 27.6 | 5.4 |
# p = 0.02, & p < 0.001, £ p = 0.05: statistical significance of the differenece between those who did and who did not report asthma or COPD amongst the participants with FEV1/FVC ratio <0.7 (GOLD 1–4 spirometry).